Insider trades › Braden Michael Leonard
Braden Michael Leonard
A corporate insider: an officer, director or owner of more than 10% of a company. Insiders report their trades to the SEC on Form 4The form insiders use to report each purchase or sale of their company's stock. It is due within two business days of the trade. · Last filing May 18, 2026
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, list Braden Michael Leonard's open-market buys and sells across companies in the last two years, with the Form 4 links.
Using 13F.ai, how did the stocks Braden Michael Leonard bought perform after the purchase compared with the S&P 500?
Using 13F.ai, are other insiders at the same companies buying or selling at the same time as Braden Michael Leonard?
Connect your AI · Plans and the 7-day free trial (card required)
Buying and selling by quarter
Dollars bought and sold on the open market over the last two years.
Bought Sold
By trade date, using the shares and price reported for each trade. Stock grants, option exercises and shares withheld for tax are left out.
Roles
The companies where this person reports as an insider, and their position at each, most recent first.
| OM Outset Medical, Inc. | 10% owner | May 18, 2026 |
| ACRS Aclaris Therapeutics, Inc. | 10% owner | Apr 27, 2026 |
| ADVM Adverum Biotechnologies, Inc. | 10% owner | Dec 5, 2025 |
| ASTC Astrotech Corporation | 10% owner | Oct 7, 2025 |
| ANTX AN2 Therapeutics, Inc. | 10% owner | Jun 16, 2025 |
| OKUR OnKure Therapeutics, Inc. | — | Oct 9, 2024 |
Roles come from the filings themselves and can change over time.
Latest open-market trades
Purchases and sales at every company, most recent filing first.
| How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss. | Filing | ||||||
|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | ACRS Aclaris Therapeutics, Inc. | Sale | 300,000 | $4.53 | $1.4M | -20.3% | Form 4 ↗ |
| Dec 4, 2025 | ADVM Adverum Biotechnologies, Inc. | Sale | 524,560 | $4.19 | $2.2M | -5.7% | Form 4 ↗ |
| Dec 3, 2025 | ADVM Adverum Biotechnologies, Inc. | Sale | 222,925 | $4.17 | $929.6K | -5.7% | Form 4 ↗ |
| Dec 2, 2025 | ADVM Adverum Biotechnologies, Inc. | Sale | 51,961 | $4.20 | $218.2K | -5.9% | Form 4 ↗ |
| Dec 1, 2025 | ADVM Adverum Biotechnologies, Inc. | Sale | 300,000 | $4.20 | $1.3M | -7.1% | Form 4 ↗ |
| Oct 3, 2025 | ASTC Astrotech Corporation | Sale | 9,166 | $5.83 | $53.4K | -41.3% | Form 4 ↗ |
| Oct 3, 2025 | ASTC Astrotech Corporation | Sale | 220,410 | $7.13 | $1.6M | -41.3% | Form 4 ↗ |
| May 28, 2025 | ANTX AN2 Therapeutics, Inc. | Sale | 200,000 | $1.09 | $218.0K | +267.3% | Form 4 ↗ |
| May 30, 2025 | ANTX AN2 Therapeutics, Inc. | Sale | 425,000 | $1.01 | $429.3K | +301.3% | Form 4 ↗ |
| May 30, 2025 | ANTX AN2 Therapeutics, Inc. | Sale | 7,000 | $1.03 | $7,210 | +301.3% | Form 4 ↗ |
| May 28, 2025 | ANTX AN2 Therapeutics, Inc. | Sale | 2.00M | $1.16 | $2.3M | +267.3% | Form 4 ↗ |
| May 28, 2025 | ANTX AN2 Therapeutics, Inc. | Sale | 100,000 | $1.16 | $116.0K | +267.3% | Form 4 ↗ |
| Mar 27, 2025 | ADVM Adverum Biotechnologies, Inc. | Buy | 16,593 | $5.19 | $86.1K | -45.1% | Form 4/A ↗ |
| Mar 27, 2025 | ADVM Adverum Biotechnologies, Inc. | Buy | 16,593 | $5.19 | $86.1K | -45.1% | Form 4 ↗ |
| Mar 26, 2025 | ADVM Adverum Biotechnologies, Inc. | Buy | 20,407 | $5.04 | $102.9K | -46.2% | Form 4 ↗ |
| Mar 26, 2025 | ADVM Adverum Biotechnologies, Inc. | Buy | 20,407 | $5.04 | $102.9K | -46.2% | Form 4/A ↗ |
| Apr 23, 2025 | ADVM Adverum Biotechnologies, Inc. | Buy | 50,000 | $2.98 | $149.0K | +12.1% | Form 4 ↗ |
| Apr 22, 2025 | ADVM Adverum Biotechnologies, Inc. | Buy | 300,000 | $3.00 | $900.0K | +4.2% | Form 4 ↗ |
| Apr 2, 2025 | ADVM Adverum Biotechnologies, Inc. | Buy | 15,209 | $4.04 | $61.4K | -31.3% | Form 4 ↗ |
| Mar 31, 2025 | ADVM Adverum Biotechnologies, Inc. | Buy | 19,566 | $4.38 | $85.7K | -35.1% | Form 4 ↗ |
| Mar 20, 2025 | ADVM Adverum Biotechnologies, Inc. | Buy | 30,600 | $5.61 | $171.7K | -55.5% | Form 4 ↗ |
| Mar 19, 2025 | ADVM Adverum Biotechnologies, Inc. | Buy | 25,000 | $4.94 | $123.5K | -52.4% | Form 4 ↗ |
| Mar 18, 2025 | ADVM Adverum Biotechnologies, Inc. | Buy | 44,341 | $4.73 | $209.7K | -45.5% | Form 4 ↗ |
| Mar 18, 2025 | ADVM Adverum Biotechnologies, Inc. | Buy | 18,000 | $4.60 | $82.8K | -45.5% | Form 4 ↗ |
| Feb 28, 2025 | ADVM Adverum Biotechnologies, Inc. | Buy | 85,068 | $4.60 | $391.3K | -34.4% | Form 4 ↗ |
| Feb 27, 2025 | ADVM Adverum Biotechnologies, Inc. | Buy | 86,802 | $4.46 | $387.1K | -29.9% | Form 4 ↗ |
| Feb 26, 2025 | ADVM Adverum Biotechnologies, Inc. | Buy | 164,886 | $4.01 | $661.2K | -22.6% | Form 4 ↗ |
Each row links to its Form 4. Since trade compares the stock’s move from the close on the trade date (or the next trading day) to its latest close with the S&P 500 over the same days, adjusted for splits and excluding dividends. It describes the stock, not what the trader made: we don’t know their purchase price, position size or later sales. A dash means the trade isn’t matched to a listed stock, or there is no closing price after it yet.
When several people report on the same filing, we list it under the first one named, so trades by someone usually listed second may be missing here. Information, not investment advice: see the disclaimer.